The Phase 3 failure has prompted Gilead Sciences and Arcus Biosciences to terminate a mid-stage study of their TIGIT asset in ...
In April 2026, Arcus Biosciences said Gilead Sciences chose not to make a continuation payment, ending option rights to ...
Arcus’s pipeline includes several promising candidates, including domvanalimab, an Fc-silent anti-TIGIT antibody, and zimberelimab, an anti-PD-1 antibody. Arcus recently announced positive results ...
Zacks Investment Research on MSN
Arcus Biosciences (RCUS) moves 7.8% higher: Will this strength last?
Arcus Biosciences, Inc. (RCUS) shares ended the last trading session 7.8% higher at $24.52. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...
FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences (NYSE: RCUS) today announced a positive update from the fourth interim analysis of ...
Arcus Biosciences is at a critical juncture, with multiple late-stage assets and a cash position nearly equal to its market cap. Casdatifan shows best-in-class potential in renal cell carcinoma, with ...
Gilead Sciences and Arcus are slimming down a phase 3 TIGIT trial to compare the lung cancer combo therapy to just Merck’s Keytruda, ditching a chemotherapy arm. The move means a little extra cash ...
(RTTNews) - Gilead Sciences, Inc. (GILD) and Arcus Biosciences (RCUS) Monday announced a positive update for the randomized, open-label joint TIGIT Phase 2 ARC-7 study in patients with first-line ...
Arcus Biosciences, Inc. (RCUS) shares ended the last trading session 7.5% higher at $18.6. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS) today announced that data from cohort A1 of the ongoing Phase 2 EDGE-Gastric study will be presented at the American Society of ...
Arcus Biosciences (NYSE:RCUS) will release its quarterly earnings report on Tuesday, 2025-05-06. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Arcus Biosciences ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results